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Abstract We have engineered a genomic HDV ribozyme to 
construct several trans-acting ribozymes for use in trans to cleave 
target RNAs. Among the 10 different combinations attempted, 
only HDV88-Trans had cleavage activity on the 13-nucleotide 
substrate, R13, in vitro. To improve the cleavage efficiency, at 
least in vitro, of the HDV88-Trans ribozyme (kclv=0.022 
min-l), we have constructed several variants that differ in 
forming stem II (length) in the pseudoknot secondary structure 
model. When cleavage rate constants were analyzed and 
compared among variants of HDV88-Trans, HDV88-Trans~4 
yielded kdv = 1.7 min 1. HDV88-Trans-4 thus represents the 
highest active genomic HDV ribozyme that functions in trans 
thus far constructed, and has activity under physiological 
conditions (pH 7.1 at 37°C with 1 mM of MgCl2). 
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to cleave target RNAs, cis-acting (intramolecular) ribozymes 
were dissected into substrates and enzymes. Earlier, efficient 
trans-acting hammerhead and hairpin ribozymes were con- 
structed and showed that they function very efficiently both 
in vitro and in vivo [7]. Similarly, both genomic and antige- 
nomic HDV ribozymes have been dissected into substrates 
and enzymes, but not yet analyzed as extensively as hammer- 
head and hairpin ribozymes. To increase their activity, non- 
physiological conditions, such as high temperature and dena- 
turants, have been used in reaction conditions. 
In the present study, we engineered the genomic HDV ri- 
bozyme to construct several trans-acting ribozymes to use in 
trans to cleave target RNAs. We succeeded in increasing their 
activity under physiological reaction conditions. 
2. Materials and methods 
1. Introduction 
Genomic and antigenomic hepatitis delta virus (HDV) 
RNAs have self-cleavage activity both in vivo and in vitro. 
As observed with hammerhead and hairpin ribozymes, the 
self-cleavage activity of HDV ribozymes requires divalent ca- 
tions and results in products with 2',3'-cyclic phosphate and 
5'-OH group at their cleavage sites. These ribozymes are com- 
pletely dissimilar, however, in primary and secondary struc- 
tures. It has been reported that both antigenomic and genomic 
ribozymes play a role in RNA processing during replication of 
the human hepatitis delta virus [1] and HDV RNA may thus 
represent the first clear example of a ribozyme that, in its 
natural form, functions in human cells. 
Several models of its secondary structure have been pro- 
posed [2]. To elucidate the functional structure of the HDV 
ribozyme and to evaluate the role of bases, we have used in 
vitro mutagenic analyses [3-5] and experiments with chemical 
probes [6]. Our results indicate that important bases lie within 
three single-stranded regions (SSrA, 726-731; SSrB, 762-766; 
and SSrC, 708-715 in Fig. 1A), and these can be drawn in a 
pseudoknot-like model of the secondary structure. Ribozymes 
are expected to form functional antisense reagents and, thus, 
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2. l. Oligonucleotides 
Oligonucleotides were synthesized bythe phosphoramidite m thod 
using a DNA/RNA synthesizer [model 392; ABI]. All reagents neces- 
sary for DNA and RNA synthesis were obtained from ABI, ABN and 
Glen Research. Purification, quantitative analysis and 5' end labels of 
these oligonucleotides were as described elsewhere [5]. 
2.2. Preparation of trans-acting enomic HDV ribozymes 
Vectors containing the sequence of mutated genomic HDV ribo- 
zyme shown in Fig. 2 were prepared using mutagenesis primers 
d(GAGGAGGCTGGGACCTCGAGCCTATAGT) for separation A 
(pUHD88-trans), d(GCGAGGAGGCTGGGCTCGAGCCTATAGT) 
for separation B, d(GCCAGCGAGGAGGCCTCGAGCCTATAGT) 
for separation C, d(CCAGCCGGCGCCAGCCTCGAGCCTATAG- 
TG) for separation F, d(GTTGCCCAGCCGGCCTCGAGCCTA- 
TAGT) for separation G and H, d(GCCATTACCGAGGGGCTCG- 
AGCCTATAGTG) for separation I and J with pUHD88 (for 
separation A, G, I and J) or pUHD88DI3 (for separation B, C, F 
and H) as templates. Ribozymes of separation D (52 nts) and E (45 
nts) were synthesized chemically. Derivatives of HDV88-trans were 
prepared by using d(TAGGCTCGAGTCCCAGCC) for Trans-0, 
d(TAGGCTCGAGGTCCCAGCC) for Trans-1, d(TAGGCTCGAG- 
TGGTCCCAGCC) for Trans-2, d(TAGGCTCGAGATGGTCCCA- 
GCC) for Trans-3, d(ATTACGAATTCTAATACGACTCACTA- 
TAGGAATCTCCCAGCCTCCTCG) for Trans-4 and d(ATTAC- 
GAATTCTAATACGACTCACTATAQGATCTCCCAGCCTCCT- 
CG) for Trans-5 from pHDV86 (for Trans-0, -1, -2 and -3) or 
pUHD88 (for Trans-4 and -5). 
2.3. Preparation of substrates 
r(GAUGGCCGGCAUG), namely R13, which was used for the 
substrate of separation A, B, C, D, E and derivatives ofHDV88-trans 
were synthesized chemically. Other substrates were prepared by in 
vitro run-off transcription. Templates for substrates were constructed 
by in vitro mutagenesis from pUHD88 (for F, G and I) or pUHD88- 
DI3 (for H and J) with mutagenesis primers, d(ACTCTAGAG- 
GATCCGAGGAGGCTGGGAC) for separation F, d(ACTCTA- 
GAGGATCCGCCAGCGAGGAGGC) for separation G and H, 
d(ACTCTAGAGGATCCACGGTCCCCTCGGA) for separation I 
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and d(ACTCTAGAGAATCCTCGGAATGTTGCCC) for separa- 
tion J. 
2.4. Plasmid DNA 
All plasmids used in this study included the T7 promoter and part 
of the HDV genomic sequence in the EcoRI-BamHI site of pUC118. 
Some had a XhoI site between the T7 promoter and the HDV se- 
quence [5]. All experiments were conducted using E. coli MV1184 as 
host cells. Plasmid DNA was prepared from an overnight culture by 
alkaline lysis and purified using QIAGEN-Tip 20 (DIAGEN, Ger- 
many). DNA sequencing was conducted ouble-stranded DNA as a 
template on a DNA sequencer (Model 373A; ABI) using dideoxy 
chaintermination with the fluorescence Taq DyeDeoxy Terminator 
system (ABI). 
2.5. Transcription in vitro 
Transcription in vitro was conducted using the AmpliScribe T7- 
Specific Transcription Kit (Epicentre Technologies, USA). A linear- 
ized vector with BamHI was used for a template of transcription i  
vitro. After the transcription reaction, an equal volume of stop solu- 
tion containing 50 mM EDTA and 9 M urea was added to stop 
transcription. After denaturation at 90°C for 2 min and quick chilling 
on ice, the transcript was isolated by extraction from denaturing 8% 
PAGE containing 7 M urea. The average yield of trans-acting ribo- 
zyme was 700 pmol (20 lag) per 1 pmol (2.2 lag) of template DNA. 
2.6. Ch, avage reactions 
For single turnover eactions, 75 pmol of unlabeled trans-acting 
ribozyme and 0.075 pmol of radiolabeled substrate were mixed in 
5 lal of 75 mM Tris-HC1 (pH 7.1). After denaturation at 90°C for 
2 minutes, the mixture was placed on ice for 30 min. Preincubation 
was conducted at the reaction temperature (37°C) for 10 min and then 
2.5 lal of prewarmed 5 mM of MgC12 was added to start the cleavage 
reaction. The final concentrations of components in this mixture were 
10 gM trans-acting ribozyme, 0.01 laM substrate, 50 mM Tris-HC1 
and 1 mM MgC12. Control reactions contained equal amounts (ca. 
2.14 lag) of tRNA instead of ribozyme. To compare the activities of 
combination A to J, final concentrations of ribozyme and substrate 
were both 0.1 laM, Cleavage reactions were conducted in 50 mM Tris- 
HC1 (pH 7.1) with 25 mM of MgC12 at 37°C or 55°C for 1 h. Samples 
(1 lal) were withdrawn at the indicated time and mixed with equal 
volumes of stop solution containing 50 mM EDTA and 9 M urea, 
and were fractionated in denaturing 20% polyacrylamide gel electro- 
phoresis. The amounts of cleaved products were quantified based on 
radioactivity intensity by use of a bioimaging analyzer (BA100; Fuji 
Film, Japan). Cleavage activity (k~lv) was indicated by the rate of 
formation of the cleaved product. For kinetic analysis, we used simple 
pseudo-first-order quations and experimental data was curve-fitted 
[Kawakami et al., unpublished results]. 
3. Results and discussion 
3.1. Comparison o f  trans-acting systems 
Several different types of trans-acting enomic and antige- 
nomic HDV ribozymes were constructed by Been [8,9], 
Branch and Robertson [10] and Wu et al. [11]. We have dis- 
sected the cis-acting genomic HDV RNA at different sites on 
the pseudoknot model for constructing ten different rans-act- 
ing HDV ribozymes (Fig. 2) and conducted cleavage reactions 
with high concentrat ions of Mg 2+ ions (25 mM), 50 mM of 
Tris-HC1 (pH 7.1) at 37°C or 55°C for 1 h. We used the above 
high concentrat ions of Mg 2+ ions to detect even low activity. 
Among these sets, only the separation A molecule, a similar 
construct made in an antigenomic one [8], was active. No 
other constructs showed activity (data not shown). The A 
trans-acting system, separated between 698 and 699, is com- 
posed of HDV88-Trans (699-770) as the enzyme and substrate 
R13 (686-698) as the substrate. To compare activity quantita- 
tively, we conducted all experiments under the same physio- 
logical conditions, i.e. pH 7.1 at 37°C with 1 mM of Mg 2+ 
ions, and obtained the rate constant of cleavage (kdv) and the 
ratio of ribozymes with active form (end point value; EP) 
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Fig. 1. Important bases in single-stranded regions (SSrA, B and C) of the genomic HDV ribozyme (HDV88) and antigenomic ribozyme are 
shown in pseudoknot secondary structure models. These data are based on our previous in vitro mutagenesis studies [3,5]. The most important 
residues (ones which cannot be substituted in any other bases) are shown by white letters against black squares. The next important residues 
(partially substitutable to some bases) are shown by letters in boxes. Unmarked letters can be substituted in any other base. Stem regions are 
shown as I to IV. 
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Fig. 2. Construction of ten types of trans-acting enomic HDV ribozymes. The nucleotide number is according to Makino et al. [23]. Sequences 
in italics are not original HDV sequences. Dotted lines indicate vector-derived sequences. White arrows indicate disconnected positions for the 
trans-acting HDV ribozyme. 
values. The kc]v value of HDV88-Trans was 0.022 min -1 and 
the EP was 51%. 
Table 1 summarizes everal kdvvalues observed in both 
antigenomic and genomic HDV ribozymes. These results sug- 
gest the following: (1) A appears to be more active than I or 
J, and (2) antigenomic ribozyme activity seems to be higher 
than the genomic. Since both genomic and antigenomic HDV 
ribozymes are represented as pseudoknot-like structures [12] 
and important residues identified from our mutagenic analyses 
[3 5] are all conserved between genomic and antigenomic 
HDV ribozymes (Fig. 1), low genomic HDV ribozyme activity 
could be due either to stabilization of an inactive conforma- 
tion or to interference in forming an active structure, as op- 
posed to an antigenomic one. 
3.2. Improving HDV88-Trans activity 
Wu et al. previously reported that a trans-acting enomic 
HDV ribozyme (683-728 and 760-770) has activity [11] and 
5' 
ggc 
U 
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ga 
6M G 
HDV88-Trans 
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3' 
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U st 
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corresponds to our I (or J), but this type showed no activity 
under our reaction conditions (they recently designed an im- 
proved, different construct [13]). The difference in construct 
from ours is that their ribozyme has a nonnatural stem IV 
sequence and different vector sequences at both 5' and 3' 
ends. It was also reported that vector sequences at both 5' 
and 3' ends of cis-acting HDV ribozyme enhance its self- 
cleavage activity [14]. Given this evidence, we focused on 
the extra sequences at both 5' and 3' ends. To improve the 
cleavage activity of HDV88-Trans, we either increased or sub- 
stituted sequences at the 3' end so that stem II (in the pseudo- 
knot secondary structure model) could be extended from 5 to 
9 base-pairs (Fig. 3, Trans-0 to Trans-5) and compared their 
activities in terms of the rate of catalysis (kdv). By extending 
stem II, we assume that the stability of the pseudoknot struc- 
ture will be increased. 
As shown in Fig. 3, kdv values increased according as stem 
II became longer, from 5 to 8 base-pairs. Among the several 
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Fig. 3. Variants of the stem II region and their kinetic activities. Small letters indicate vector-derived sequences. 
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Table 1 
Comparison of kclv values of several types of trans-acting HDV ri- 
hozymes 
HDV ribozymes kinetic constants 
(k,l,,) 
Separation A
Genomic 
Antigenomic 
Separation 1or J 
Genomic 
Antigenomic 
0.022 min 1 (pH 7.1 at 37°C, 
in this paper) 
~2.8~ min -a (pH 7.4 at 55°C, 
Perrota and Been [8]) 
1.5 rain ~ (pH 8.0 at 37°C, 
Been et al. [9]) 
(pH 7.1 at 37°C, 
in this paper) 
0.011 mint  (pH 7.2 at 50°C, 
Wu et al. [11]) 
0.52 min 1 (pH 8.0 at 37°C, 
Been et al. [9]) 
constructs we made, Trans-4 (8 base-pairs) showed the highest 
activity. When the rate constants were compared for HDV88- 
Trans versus Trans-4, the later construct has nearly 80-fold 
higher kdv values. The stabilities of stem II at 37°C in 1 M 
NaC1 were calculated based on the nearest neighbor param- 
eters [15,16]. The free energy changes by formation of stem II 
were -5 .5  kcal.mol 1 (HDV88-Trans), --7.2 kcal-mol -I 
(Trans-0), --8.5 kcal.mol 1 (Trans-1, -2 and -3), -10,2  
kcal.mo1-1 (Trans-4), and -12.3 kcal.mol 1 (Trans-5), respec- 
tively. These values may not be accurate by dangling ends of 
stem II and the effect of stacking with stem Il l ,  but seem to 
correlate well with the logarithm of k~,jv values (data not 
shown). This result indicates that stabilization of the local 
structure at stem II might affect fairly directly the activity 
of HDV ribozyme. Been and Perrotta reported an interaction 
between SSrA and SSrB in antigenomic HDV ribozyme [17]. 
This interaction should bring stem II to near the active site. In 
the case of Tetrahymena group I intron, a local structure 
(P5abc) is indispensable to change the core structure into 
the active form [18]. Furthermore in the cleavage of tRNA 
by Pb 2+ ions, sufficient Mg 2+ ions to ensure proper folding of 
tRNA are required, and the cleavage rate correlates with the 
structure of the active site [19]. In our case, a stable stem II 
structure may have an influence of the core structure and of 
arrangement or distance of the functional groups at the active 
site. By further extending the stem II structure (beyond 8 
base-pairs, Trans-5), we observed a 5-fold decrease in the 
k+ value. This result suggests that stem II of the trans-acting 
genomic HDV ribozyme plays an essential role in maintaining 
the pseudoknot structure. Too rigid a stem structure, how- 
ever, makes the entire molecule inflexible and, subsequently, 
it inhibits structural changes necessary for expressing its ribo- 
zyme activity. This speculation agrees with previous results 
showing that stem II is an important region for formation 
of active core [9,20] and the GGAGA sequence at the 3'- 
end of the HDV ribozyme is important in expressing its ac- 
tivity under denaturation conditions with urea or formamide 
[21,22] because, in the pseudoknot structure model, these res- 
idues are located in stem II, meaning stable stem II structure 
is important o ribozyme activity under denatured conditions. 
The construct isolated here, Trans-4, obtained k,,~v activity 
comparable to the hammerhead and hairpin ribozymes. 
HDV88-Trans-4 represented the highest active genomic 
HDV ribozyme (1.7 min i) that functions in trans under 
physiological conditions (pH 7.1 at 37°C with 1 mM of 
MgCI2). Taking these results together, we are now construct- 
ing several minimal trans-acting HDV ribozymes derived from 
Trans-4. 
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